Bristol-Myers Squibb Company (BMY) : During the past 4 weeks, traders have been relatively bearish on Bristol-Myers Squibb Company (BMY), hence the stock is down -17.98% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -15.77% relative to the S&P 500. The 4-week change in the price of the stock is -15.94% and the stock has fallen -15.41% in the past 1 week.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $62.00 on Friday but the bulls could not build on the opening and the stock topped out at $64.77 for the day. The stock traded down to $61.56 during the day, due to lack of any buying support eventually closed down at $63.28 with a loss of -15.99% for the day. The stock had closed at $75.32 on the previous day. The total traded volume was 86,212,615 shares.
The stock has recorded a 20-day Moving Average of 16.32% and the 50-Day Moving Average is 13.9%. Bristol-Myers Squibb Company has dropped 10.68% during the last 3-month period . Year-to-Date the stock performance stands at -6.97%.
Bristol-Myers Squibb Company (BMY) : The highest level Bristol-Myers Squibb Company (BMY) is projected to reach is $100 for the short term and the lowest estimate is at $48. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $74.71 and the possibility the share price can swing is $13.79.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.